• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, December 11, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Better choice of contraceptives can prevent breast cancer

Bioengineer by Bioengineer
May 28, 2021
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

An EPFL study into the distinct biological effects of different progestins on the breast shows that contraceptive-related breast cancer can be prevented by more informed choices about the composition of contraceptives.

IMAGE

Credit: EPFL

Hormonal contraceptives, e.g. the pill, the patch, and the vaginal ring, contain synthetic hormones that prevent pregnancy by either stopping ovulation, changing the cervical mucus to stop sperm from passing through the cervix and finding an egg, or changing the womb’s lining to prevent a fertilized egg from being implanted in it.

Despite their widespread use, hormonal contraceptives are known to increase the risk of breast cancer, which is the most common cause of cancer-related death among women worldwide, and also topped the list of most commonly diagnosed cancers in 2020.

The main component of hormonal contraceptives are progestins, which, mimic the female sex hormone progesterone. Progesterone is involved in a number of biological processes, including the menstrual cycle, pregnancy, and various aspects of fetal development, like brain programming.

Now, a team of scientists led by Professor Cathrin Brisken at EPFL’s School of Life Sciences, have taken a thorough and close look at the different biological effects that different progestins in hormonal contraceptives have on the breast tissue – the mammary epithelium. The work is published in EMBO Molecular Medicine.

“Although we know how different contraceptive formulations affect the cardiovascular system, we know little about their effects on the breast,” says Brisken. “So we developed new approaches to compare the most commonly used progestins in different hormonal contraceptives and were surprised to find that some of them stimulate cell proliferation in the breast – while others do not.”

The researchers tested the effects of prolonged exposure to different progestins on human breast epithelial cells or HBECs, which line the inner layer of the breast. To do this, they developed “humanized” mouse mammary glands by grafting breast epithelial cells from donated human breast tissue from reduction mammoplasty samples into the animals’ milk ducts and monitoring their growth in vivo.

“We found that HBECs engraft and proliferate in mouse milk ducts, maintaining hormone receptor expression and hormone responsiveness, which are crucial factors for establishing a relevant preclinical model and thereby to foster translational research,” says Brisken.

The team realized that what distinguished the stimulatory and the innocuous progestins were their “androgenic properties” – a technical term for substances that trigger the development of male characteristics, such as body hair, muscle mass etc. This isn’t as strange as it sounds: progesterone, mostly known as a female hormone, is used for the production of the famous male hormone testosterone in both women and men.

Some progestins have androgenic properties, acting like testosterone; some actually block them. The key is a protein known as the androgen receptor, which, when activated by an androgenic progestin, travels into the cell’s nucleus where it regulates the expression of certain genes.

Working with the epithelial cells in a mouse model, the researchers found that androgenic progestins act through the androgen receptor to induce the expression of the protein Rankl, which plays an important role in cell proliferation in the mammary epithelium. This effect was not seen with anti-androgenic progestins.

The study showed that androgenic – but not anti-androgenic – progestins promote cell proliferation. “Exposing human breast epithelia to androgenic progestins for prolonged periods of time caused hyperproliferation and changes in the cells that are associated with early, pre-malignant lesions – at least in xenografted human breast epithelia,” says De Martino.

“Hormonal contraception exposes women to different progestins with or without estrogen,” says Brisken. “The androgenic properties of progestins determine their biological activity in the breast epithelium, and reveal an unexpected role for androgen receptor activity in the proliferation of breast epithelial cells.”

The crucial insight of the study is that progestins with anti-androgenic activity may be a safer option with regards to breast cancer risk than testosterone-related compounds, e.g. the widely used contraceptive levonorgestrel (“Plan B”). “It might be possible to prevent breast cancer associated with contraception by making more informed choices taking the molecular composition of a contraceptive into account,” concludes Brisken.

###

Other contributors

University Hospital of Lausanne (CHUV)

International Cancer Prevention Institute

Funding

Swiss National Science Foundation

Swiss Cancer League

Biltema ISREC Foundation Cancera Stiftelsen

Mats Paulssons Stiftelse

Stitelsen Stefan Paulssons Cancerfond

Joint Action and Learning Initiative (JALI)

Media Contact
[email protected]
[email protected]

Original Source

https://www.embopress.org/doi/full/10.15252/emmm.202114314

Related Journal Article

http://dx.doi.org/10.15252/emmm.202114314

Tags: BiologyBreast CancercancerMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Anne Peery, MD, MSCR, associate professor of medicine, UNC School of Medicine

Doctors discover many patients at UNC’s Inflammatory Bowel Disease Clinic screen positive for malnutrition

December 8, 2023
Oxygen study enters uncharted territory

A dynamic picture of how we respond to high or low oxygen levels

December 8, 2023

Milestones in Europe: First results in using new tools to tackle respiratory syncytial virus

December 8, 2023

Engaging heterosexual men more effectively could slash HIV infections in Uganda

December 8, 2023
Please login to join discussion

POPULAR NEWS

  • Figure 1

    Understanding rapid tendon regeneration in newts may one day help human athletes

    85 shares
    Share 34 Tweet 21
  • Photonic chip that ‘fits together like Lego’ opens door to semiconductor industry

    36 shares
    Share 14 Tweet 9
  • Study finds increasingly popular oral nicotine pouches do little to curb smokers’ cravings

    35 shares
    Share 14 Tweet 9
  • SMART researchers pioneer novel microfluidic method to optimise bone marrow stem cell extraction for advanced cell therapies

    35 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Landscape for AML patients evolving rapidly as research discoveries advance new treatments

Cell therapy appears safe and effective for lymphoma in remission

ASH: Targeted oral therapy reduced disease burden and improved symptoms for patients with rare blood disorder

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 58 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In